Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Evidence-based classification of genes implicated in craniosynostosis disorders using the ClinGen curation framework.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Gene Portals: A Framework for Integrating Clinical, Functional, and Structural Evidence into Rare Disease Variant Classification.

medRxiv : the preprint server for health sciences·2026
Same author

Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.

Therapeutic advances in rare disease·2026
Same author

Prioritizing topics for a clinical practice guideline on SATB2-associated syndrome: methodological rigor vs clinical usability.

Journal of clinical epidemiology·2026
Same author

Functional characterization of pathogenic SATB2 missense variants identifies distinct effects on chromatin binding and transcriptional activity.

HGG advances·2025
Same author

A clinical and genotype-phenotype analysis of MACF1 variants.

American journal of human genetics·2025
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Jun 28, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

ファブリー病 (Fabry's disease) とはファブリー病 (Fabry's disease) とはファブリー病 (Fabry's disease) とはファブリー病 (Fabry's disease) とはファブリー病

Yuri A Zarate1, Robert J Hopkin

  • 1Cincinnati Children's Hospital Medical Center, Division of Human Genetics, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Lancet (London, England)
|October 23, 2008
PubMed
まとめ
この要約は機械生成です。

ファブリー病は遺伝的疾患で,GLA遺伝子変異の結果,アルファ-ガラクトシダゼA欠乏症を引き起こす. 早期の酵素置換療法は,臓器の機能と症状を改善しますが,臓器機能不全には追加の治療が必要になる可能性があります.

さらに関連する動画

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

関連する実験動画

Last Updated: Jun 28, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

科学分野:

  • 遺伝学 遺伝学とは
  • メタボリック障害 メタボリック障害
  • リソソーム性貯蔵病 リソソーム性貯蔵病

背景:

  • ファブリー病は,GLA遺伝子変異に起因するX結合型リソソーム貯蔵障害である.
  • このアルファ-ガラクトシダゼAの欠乏は,グリコスフィンゴリピドの蓄積を引き起こし,著しい罹病率と死亡率につながります.
  • このレビューには,疫学,病理生理学,臨床的表れ,診断,管理,予防,および生活の質への影響が含まれています.

研究 の 目的:

  • ファブリー病の包括的な概要を提供するために.
  • 初期の酵素置換療法 (ERT) の重要性を強調する.
  • ERTと共に個別化された治療戦略の必要性を議論する.

主な方法:

  • ファブリー病の側面に関する文献レビュー.
  • ERTを含む現在の治療戦略の分析.
  • 臨床結果と生活の質に関するデータの評価.

主要な成果:

  • ERTは,心臓の質量を改善し,腎臓の機能を安定させ,痛み,発汗,消化器官,聴覚,肺の症状を軽減することに有望であることが示されています.
  • ERTを早期に開始することは,主要な影響を受けた臓器でのより良い結果のために非常に重要です.
  • 多くの患者は,特に既存の臓器機能不全を有する患者は,追加の症状特異的な治療を必要とします.

結論:

  • 酵素置換療法は,特に早期に開始された場合,ファブリー病の管理の礎石です.
  • ERTと症状特異的な治療を組み合わせたマルチモダルの治療アプローチは,最適な患者のケアのためにしばしば必要である.
  • 長期的な治療の有効性と結果を確立するためにさらなる研究が必要である.